Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Gastroesophageal Cancer – Current Treatment – Current Treatment: Physician Insights – Gastroesophageal Cancer (US)
The gastroesophageal cancer therapy market is gaining a lot of traction. In the HER2-positive segment, trastuzumab-based regimens, with or without Keytruda, continue to dominate. Meanwhile, the…
Hospital-Treated Gram-Negative Infections – Current Treatment – Current Treatment: Physician Insights – Hospital-Treated Gram-Negative Infections (US)
Most inpatients with hospital-treated gram-negative infections (GNIs) are successfully treated empirically with generic antibiotics. These agents continue to dominate the hospital-treated GNI…
Gastroesophageal Cancer – Current Treatment – Treatment Sequencing – Gastroesophageal Cancer (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Chronic Obstructive Pulmonary Disease – Access & Reimbursement – Access & Reimbursement – Chronic Obstructive Pulmonary Disease (US)
The dynamics within the LAMA, LABA/LAMA, LABA/ICS FDC, and LABA/LAMA/ICS FDC drug classes will continue to shape the U.S. COPD market, as will the market entry of Verona’s nebulized PDE-3/PDE-4…
Squamous Cell Carcinoma of the Head and Neck – Unmet Need – Unmet Need – Recurrent or Metastatic Non-Nasopharyngeal Squamous Cell Carcinoma of Head and Neck (US/EU)
Recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck is an aggressive malignancy associated with a high recurrence rate. The approval of immune checkpoint…
Hospital-Treated Gram-Negative Infections – Landscape & Forecast – Disease Landscape & Forecast (G7)
Due to the rising rates of antimicrobial resistance, antibiotics with activity against drug-resistant gram-negative pathogens are essential. Antibiotics such as carbapenems, which have historically…
